Skip to main content
Fig. 1 | BMC Ophthalmology

Fig. 1

From: The effect of insulin on response to intravitreal anti-VEGF injection in diabetic macular edema in type 2 diabetes mellitus

Fig. 1

Best-corrected visual acuity and central macular thickness outcome at baseline and the end of 12 months (final) of anti-VEGF therapy by type of diabetes treatment. BCVA: best-corrected visual acuity; approxETDRS: approximate early treatment diabetic retinopathy study; CMT: central macular thickness; OHA: oral hypoglycemic agent; error bars represent 95% confidence interval for mean; p value is for comparing the BCVA and CMT between the treatment groups at each visit

Back to article page

BMC Ophthalmology

ISSN: 1471-2415

Contact us